3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: A Next-Generation H+,K+-ATPase Inhibitor for Gastric Acid Secretion Research

Introduction

The regulation of gastric acid secretion is fundamental to gastrointestinal physiology and the pathogenesis of gastric acid-related disorders, including peptic ulcer disease and gastroesophageal reflux. Central to this regulatory process is the H+,K+-ATPase enzyme, commonly known as the gastric proton pump. Pharmacological targeting of this signaling pathway underpins the development of advanced antiulcer agents for research and potential therapeutic innovation. Among the most promising of these is 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845), a highly selective and potent H+,K+-ATPase inhibitor that offers new possibilities for gastric acid secretion research.

Mechanism of Action of 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide

Targeting the Proton Pump: Specificity and Potency

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide acts by directly inhibiting the H+,K+-ATPase enzyme located in the parietal cells of the gastric mucosa. This inhibition disrupts the final step of gastric acid production—the exchange of intracellular hydrogen ions for extracellular potassium ions—thus suppressing gastric acid secretion at its source. With an IC₅₀ of 5.8 μM for the enzyme and an exceptionally low IC₅₀ of 0.16 μM for histamine-induced acid formation, this compound demonstrates remarkable efficacy and selectivity as a gastric acid secretion inhibitor.

Comparative Biochemical Profile

Unlike classic proton pump inhibitors (PPIs) such as omeprazole, which require activation under acidic conditions and covalently modify cysteine residues on the proton pump, this compound provides direct, reversible inhibition. Its molecular structure (C₁₇H₁₉N₃O₃S, MW 345.42) and trifluoromethoxy substitution confer high potency and stability, as validated by high-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) analyses, ensuring a purity of approximately 98%—a critical factor for reproducibility in experimental studies.

Advanced Research Applications in Gastric Acid-Related Disorders

Antiulcer Activity and Experimental Models

The robust antiulcer activity of this compound positions it as a valuable tool for antiulcer activity study and the development of peptic ulcer disease models. By precisely modulating the H+,K+-ATPase signaling pathway, researchers can dissect the pathophysiology of acid-induced mucosal injury, evaluate novel protective agents, and elucidate the mechanisms underlying mucosal defense and repair. Its efficacy in inhibiting both basal and stimulated acid secretion makes it ideal for models that mimic clinical scenarios of dysregulated acid production.

Gastric Acid Secretion Research and Pathway Analysis

The use of this H+,K+-ATPase inhibitor extends to detailed investigations of the proton pump inhibition pathway. Its selective action allows for the dissection of downstream effects on epithelial integrity, mucosal immunity, and the gut-liver-brain axis—an emerging field with profound implications for systemic diseases. For example, insights into the regulation of the gut–liver–brain axis were highlighted in a recent study examining neuroinflammation in hepatic encephalopathy models (see Kong et al., 2025), where modulation of gastric and microbial factors influenced neuroinflammatory outcomes. While the referenced study primarily addressed the neurological sequelae of hepatic dysfunction, its findings emphasize the interconnectedness of gut and systemic physiology and underscore the need for precise experimental tools such as this compound for pathway-specific research.

Comparison with Alternative Gastric Acid Inhibitors

Distinct Mechanistic Advantages

Traditional PPIs like omeprazole, lansoprazole, and pantoprazole have long been the mainstays in both clinical and experimental research. However, these agents are limited by their dependence on acidic activation, variable bioavailability, and the potential for tachyphylaxis with long-term use. In contrast, 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide offers several research advantages:

• Direct, reversible inhibition of H+,K+-ATPase, enhancing experimental control.
• Superior potency in both basal and stimulated acid secretion assays.
• Minimal off-target effects due to its chemical specificity.
• High solubility in DMSO (≥17.27 mg/mL), facilitating in vitro and in vivo application.

Moreover, the compound’s stability profile (optimal at -20°C, not recommended for long-term solution storage) and water/ethanol insolubility broaden its compatibility with a range of experimental systems, especially where organic solvents are preferred for delivery.

Implications for Peptic Ulcer Disease Models

In peptic ulcer disease models, precise modulation of gastric acid secretion is crucial. The high selectivity and rapid action of this compound allow for acute and chronic experimental designs to dissect mucosal injury and repair dynamics. This granularity is not achievable with less selective or slower-acting agents, thus advancing the frontier of antiulcer agent research.

Integration with Gut–Liver–Brain Axis and Systemic Disease Models

Expanding the Scope: From Gastric Physiology to Neuroinflammation

Recent research has spotlighted the gut–liver–brain axis as a key mediator of systemic health, particularly in complex diseases such as hepatic encephalopathy. In the seminal study by Kong et al. (2025), modulation of gut microbiota through Bifidobacterium and fecal microbiota transplantation was shown to influence neuroinflammatory markers as assessed by [18F]PBR146 PET imaging, even though the primary focus was not on gastric acid inhibition per se. The results highlighted how gut-derived factors, potentially including acid secretion and mucosal integrity, can impact neuroinflammation and systemic disease progression.

By employing a highly selective gastric acid secretion inhibitor such as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, researchers can more precisely interrogate the contribution of gastric acid flux to gut microbiota composition, intestinal permeability, and downstream neuroimmune interactions. This provides a powerful tool for exploring the mechanistic links between gastric physiology and systemic pathologies.

Application in Multi-Organ Crosstalk Studies

The integration of this compound into multi-organ crosstalk studies—particularly those investigating the impact of gastric acid on the gut-liver axis, microbiome shifts, and neuroinflammation—represents an innovative application that distinguishes it from conventional antiulcer agents. Such studies may build upon, but expand beyond, findings like those of Kong et al., by enabling targeted manipulation of gastric acid as a primary variable in complex disease models.

Optimizing Experimental Design and Product Handling

Formulation and Storage Considerations

For optimal experimental outcomes, the compound should be dissolved in DMSO to achieve concentrations of at least 17.27 mg/mL, given its insolubility in water and ethanol. Researchers should store the solid at -20°C and avoid prolonged solution storage to maintain compound integrity. The high purity and robust QC (HPLC, NMR) offered by APExBIO provide additional assurance for reproducible results in demanding research settings.

Compliance and Ethical Use

It is essential to note that this product is intended strictly for scientific research use and is not approved for diagnostic or clinical application. Proper handling and institutional compliance should be observed at all times.

Conclusion and Future Outlook

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide stands at the forefront of modern gastric acid secretion research as a potent, selective, and versatile H+,K+-ATPase inhibitor. Its unique pharmacological profile and advanced QC make it an indispensable asset for antiulcer activity study, peptic ulcer disease model development, and systemic investigations into the proton pump inhibition pathway. By enabling more precise experimental manipulation, this compound supports the next generation of research into gastric acid-related disorders and the broader landscape of gut–liver–brain axis studies. As innovative research continues to bridge gastrointestinal and systemic health, APExBIO's A2845 offers a critical tool for pioneering new scientific insights.

Explore the full product details and ordering information for 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (A2845) on the APExBIO website.